65,437 trials
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Pulmonary Arterial Hypertension
Primary: Number of Participants With Successful Completion of the 16 Week Treatment Period. — 32 participants
Cigarette Smoking · Nicotine Dependence · Post-traumatic Stress Disorder
Primary: Number of Participants With 7-day Point Prevalence Smoking Abstinence — 8; 11 Participants
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Month 3 — -7.2; -7.3 mmHg
Ovarian Cancer
Primary: Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent…
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1 — 0; 1 participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29 — 0.058; 0.088; 0.060; 0.073 Liter — p=0.009
Refractive Error
Primary: Percentage of Subjects Satisfying the "no Re-fit" Criteria in Both Eyes — 93.3; 94.6 percentage of subjects
Opioid Dependence
Primary: Successful Naltrexone Initiation — 11 Participants
Cutaneous Abscess
Primary: Number of Participants With Antibiotic Usage at the Time of the ED Visit — 97; 96 Participants
Stage IA Fallopian Tube Cancer · Stage IA Ovarian Cancer · Stage IB Fallopian Tube Cancer
Primary: Progression-free Survival (PFS) — 5.9; 6.5 Months
Atrophic Vaginitis
Primary: Primary Endpoint (Vaginal Cytology + Vaginal pH) Equivalence — 42; 45 Participants
Infections, Meningococcal
Primary: Anti-Meningitis Antibody Titers by Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 3415.3; 2860.4; 1577.4; 5092.5 EL.U/mL
Multiple Sclerosis
Primary: Change in Cognitive Function Over Time — -1.5; -1.2; -1.2 units on a scale — p=0.17
Multiple Sclerosis · Optic Neuritis · Transverse Myelitis
Primary: Rate of Development of Clinical Definite Multiple Sclerosis (CDMS) Over 10 Years — 58; 69 Percent cumulative probability — p=0.001